Zealand Pharma

Major Shareholding Notification • Jul 30, 2015

Copenhagen, 2015-07-30 10:23 CEST (GLOBE NEWSWIRE) -- Copenhagen, 30 July 2015
– Zealand informs that the company has received a major shareholder
announcement from Bpi Groupe, 27-31 AV du Général Leclerc, 94700
Maisons-Alfort, France (French registration no. 507 523 678 R.C.S. Créteil).

As stated in Company Announcement no. 6/2015 of 18 March 2015, Innovation
Capital no longer manages nor controls the voting rights of CDC Entreprises
Capital Investissement ("CDC ECI").

CDC ECI is controlled by Bpi France Participation which is controlled by Bpi
Groupe.

Pursuant to Section 29 of the Danish Securities Act, cf. Executive order no.
668 of 25 June 2012 on major shareholders and the Danish Companies Act section
55, cf. section 56, it has been announced to Zealand that Bpi Groupe (via its
subsidiary CDC ECI) indirectly holds nominally DKK 1,190,215 shares in Zealand
Pharma A/S, corresponding to 5.06 % of the company’s share capital and voting
rights.

                                  ?????

For further information, please contact:

Hanne Leth Hillman, Senior Vice President for Investor Relations and
Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company with world leading expertise in the identification, design and
development of novel peptide-based medicines, with competences spanning also
in-house clinical trial design and management. The company is advancing a
proprietary pipeline of novel medicines alongside a portfolio of products and
development projects under license collaborations - and with a therapeutic
focus in the fields of metabolic diseases and acute care indications.

Zealand’s first invented medicine, lixisenatide, is a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, which is marketed globally
(ex-US) as Lyxumia® under a license agreement with Sanofi, covering also
LixiLan, a new fixed-ratio combination of lixisenatide and insulin glargine
(Lantus®) in Phase III development. Lixisenatide was submitted for regulatory
approval in the US in late July 2015, and filings for LixiLan are planned for
Q4 2015 in the US and Q1 2016 in the EU.

The proprietary pipeline includes danegaptide (prevention of Ischemic
Reperfusion Injury) in Phase II and the stable glucagon analogue, ZP4207 in two
clinical programs; a single-use rescue pen (severe hypoglycemia) in preparation
for Phase II and a multiple-dose version (mild to moderate hypoglycemia) in
Phase I, as well as several preclinical peptide therapeutics.

Zealand currently has global license agreements and collaborations with Sanofi,
Helsinn Healthcare and Boehringer Ingelheim.

Zealand is based in Copenhagen, Denmark. For further information:
www.zealandpharma.com and follow us on Twitter @ZealandPharma.